ESTRO 2024 - Abstract Book

S1858

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

In current clinical practice, only 8% of non-spinal bone metastases referred for EBRT would be eligible to undergo MR-HIFU as alternative to EBRT for pain palliation. We observed substantial differences in eligibility rates among institutions, primarily due to differences in patient-related factors. Final results of the Further trial on effectiveness of MR-HIFU compared to EBRT on pain palliation of metastatic bone disease are expected in 2026.

Keywords: Bone metastases, eligibility, MR-HIFU

610

Digital Poster

Targeted RT study: results on acute toxicity of targeted therapies and radiotherapy

Dinah Konnerth 1 , Aurélie Gaasch 1 , Christoph Benedikt Westphalen 2,3 , Kathrin Heinrich 2,3 , Maximilian Niyazi 4,1 , Chukwuka Eze 1 , Paul Rogowski 1 , Sebastian Norbert Marschner 1,5 , Annemarie Zinn 1 , Claus Belka 1,5,6 , Stefanie Corradini 1 , Stephan Schönecker 1 1 Ludwig-Maximilians-Universität, Radiation Oncology, Munich, Germany. 2 Comprehensive Cancer Center Munich & Department od Medicine III, University Hospital Munich, LMU Munich, Oncology, Munich, Germany. 3 German Cancer Consortium, Oncology, Munich, Germany. 4 University Hospital Tübingen, Radiation Oncology, Tübingen, Germany. 5 German Cancer Consortium, Radiation Oncology, Munich, Germany. 6 Bavarian Cancer Research Center, Radiation Oncology, Munich, Germany

Purpose/Objective:

This prospective study aimed to evaluate the feasibility and side effects of integrating targeted therapies (TT) with radiotherapy (RT) in cancer patients, as there is limited prospective data on this combination. The goal was to contribute to the existing knowledge about administering targeted substances alongside radiotherapy.

Material/Methods:

The study enrolled patients diagnosed with histologically confirmed cancer who underwent external beam radiotherapy (EBRT) in combination with targeted therapy at a single institution between March 1, 2020, and December 31, 2021. This study, named the "Targeted RT Study," was registered in the German Clinical Trials Register. We systematically documented the toxicity profiles of various targeted therapies, and the assessment of acute toxicity adhered to the National Cancer Institute Common Terminology Criteria for Adverse Events Version v5.0 guidelines.

Results: